and oblimersen could become the first FDA-approved BCL-2 inhibitor. BCL-2 antagonists will probably begin their commercial lives as products that disable the anti-apoptotic machinery and restore ...

1 provide one explanation. The KSHV cyclin directs cellular cyclin-dependent kinase 6 (CDK6) to phosphorylate cellular Bcl-2, an inhibitor of apoptosis. Phosphorylation renders Bcl-2 unstable ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...

including a BTK inhibitor and a BCL-2 inhibitor in December 2023. It was approved for the MCL indication in the United States in January 2023. Jaypirca is one of Lilly’s several new drugs that ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...